Using Local sIgE Threshold to Refine the Diagnosis of Local Allergic Rhinitis
- 2 March 2026
- journal article
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (8) , 820-830
Abstract
Background: Local allergic rhinitis (LAR) is a chronic rhinitis (CR) phenotype with localized IgE production but no systemic atopy. Diagnosis relies on the nasal allergen challenge (NAC), but its correlation with the underlying immunological endotype is unclear, necessitating a more reliable biomarker. Therefore, this study was conducted to evaluate a local specific immunoglobulin E (sIgE) threshold for diagnosing house dust mite (HDM)‐sensitized LAR and compare its immunological relevance to the conventional NAC‐based method. Methods: This prospective study enrolled 181 CR patients without systemic atopy and 146 healthy controls. All CR patients underwent NAC. Local sIgE levels of Dermatophagoides pteronyssinus and Dermatophagoides farinae were measured in nasal secretions. A diagnostic threshold was established using the 95th percentile from the healthy cohort. The NAC and sIgE‐based stratifications were then compared by analyzing patients’ nasal cytokine profiles. Results: Classification based on NAC positivity did not reveal significant differences in local sIgE or a consistent type 2 inflammatory signature. In contrast, stratification using the established local sIgE threshold (≥ 0.14 kUA/L) identified a local sIgE‐high group with significantly elevated levels of type 2 cytokines (IL‐4, IL‐5, CCL5, and CCL11) compared to the sIgE‐low group (all p < 0.05). Furthermore, local sIgE levels positively correlated with these type 2 cytokines in the sIgE‐high group. Conclusion: A local sIgE threshold reliably identifies an immunologically distinct LAR endotype, aligning diagnosis with its type 2 pathophysiology. This biomarker‐driven approach offers a precise tool to refine diagnostic algorithms and improve patient selection for targeted therapies.Keywords
Funding Information
- National Key Research and Development Program of China (2022YFC2504100)
- National Key Research and Development Program of China (2023YFC2410200)
- National Natural Science Foundation of China (82471132)
- National Natural Science Foundation of China (82071022)
This publication has 33 references indexed in Scilit:
- Stapokibart for moderate-to-severe seasonal allergic rhinitis: a randomized phase 3 trialNature Medicine, 2025
- Local Allergic RhinitisThe Journal of Allergy and Clinical Immunology: In Practice, 2024
- Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): an investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trialeClinicalMedicine, 2024
- Role of autophagy and mitophagy of group 2 innate lymphoid cells in allergic and local allergic rhinitisWorld Allergy Organization Journal, 2024
- Clinical characteristics of local allergic rhinitis sensitized to house dust mites in AsiaEuropean Archives of Oto-Rhino-Laryngology, 2023
- Chemokines and chemokine receptors in allergic rhinitis: from mediators to potential therapeutic targetsEuropean Archives of Oto-Rhino-Laryngology, 2022
- Allergen Immunotherapy for Local Respiratory AllergyCurrent Allergy and Asthma Reports, 2020
- Mucosal IgE immune responses in respiratory diseasesCurrent Opinion in Pharmacology, 2019
- Local production of IgE in the respiratory mucosa and the concept of entopy: does allergy exist in nonallergic rhinitis?Annals of Allergy, Asthma & Immunology, 2010
- Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitisJournal of Allergy and Clinical Immunology, 2009